1-year follow-up of the use of hydroxycarbamide and didanosine in HIV infection [22]

Lancet

Volumn 348, Issue 9021, 1996, Pages 203-204

  Vila, J ^a   Biron, F ^a   Nugier, F ^a   Vallet, T ^a   Peyramond, D ^a  

^a Lyon   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; DIDANOSINE; HYDROXYUREA;

ANTIVIRAL ACTIVITY; CLINICAL ARTICLE; DRUG TOLERABILITY; FOLLOW UP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LETTER; LYMPHOID TISSUE; PRIORITY JOURNAL;

EID: 0029933819     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(05)66157-0     Document Type: Letter

References (5)

1. F Biron F Lucht D Peyramond Anti-HIV activity of the combination of didanosine and hydroxyurea in HIV-1–infected individuals J Acquir Immune Defic Synd Hum Retrovirol 10 1995 36 40
2. S Malley JM Grange F Hamedi-Sangsari JR Vila Suppression of HIV production in resting lymphocytes by combining didanosine and hydroxamate compounds Lancet 343 1994 1292
3. S Malley JM Grange F Hamedi-Sangsari JR Vila Synergisitc anti-HIV-1 effect of hydroxamate compounds with 2′,3′-dideoxyinosine in infected resting human lymphocytes Proc Natl Acad Sci USA 91 1994 11017 11021
4. F Lori A Malykh A Cara Hydroxyurea as an inhibitor of human immunodeficiency virus-type 1 replication Science 266 1994 801 805
5. Montaner J, Zala C, Raboud J, et al. A pilot study of Hydroxyurea (HO-urea) as adjuvant therapy among patients with advanced HIV disease receiving Didanosine (ddI) therapy. Third Conference on Retroviruses and Opportunistic Infections, Washington DC, USA, Jan28–Feb 1, 1996.